Ascendis Pharma (ASND)
(Real Time Quote from BATS)
$146.13 USD
+6.56 (4.70%)
Updated Sep 17, 2024 03:48 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Ascendis Pharma A/S [ASND/]
Reports for Purchase
Showing records 261 - 280 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TC-hGH Phase 3 Data Timeline Adjustment for Overenrollment
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Top Picks for 2018
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Equity Research
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Financing Provides Cushion Beyond Phase 3 Pediatric GHD Results in H2:18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Competition Reduced by Clinical Efficacy Failure; Increasing Penetration and PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Week Ahead - Week of September 18, 2017
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
June and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q1:17 Financial Update: Cash Runway into Late 2018 Covers Pipeline Progress; Reiterate OUTPERFORM and Raising PT to $36 for Time Value and FX
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
May and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L